Nonsmall cell lung cancer

The objective of this review is to report the Clinical Year in Review proceedings in the field of nonsmall cell lung cancer that were presented at the 2012 European Respiratory Society Congress in Vienna, Austria. Various topics were reviewed, including epidemiology, screening, diagnosis, treatment, prognosis, and palliative and end of life care.

[1]  F. Khuri,et al.  Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis. , 2012, Lung cancer.

[2]  C. Lee,et al.  Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. , 2012, Lung cancer.

[3]  F Levi,et al.  European cancer mortality predictions for the year 2012. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Hyae-Young Kim,et al.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Wild,et al.  Occupational risk factors have to be considered in the definition of high-risk lung cancer populations , 2012, British Journal of Cancer.

[6]  E. Feuer,et al.  Impact of Reduced Tobacco Smoking on Lung Cancer Mortality in the United States During 1975–2000 , 2012, Journal of the National Cancer Institute.

[7]  B. Brunekreef,et al.  Ten principles for clean air , 2012, European Respiratory Journal.

[8]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[9]  R. Heist,et al.  Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Labianca,et al.  Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST) , 2012, British Journal of Cancer.

[11]  V. Torri,et al.  Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Whitson,et al.  Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis. , 2011, The Annals of thoracic surgery.

[13]  M. Echteld,et al.  End-of-life care and circumstances of death in patients dying as a result of cancer in Belgium and the Netherlands: a retrospective comparative study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Wain,et al.  Outcomes of patients with isolated adrenal metastasis from non-small cell lung carcinoma. , 2011, The Annals of thoracic surgery.

[15]  R. V. van Klaveren,et al.  A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). , 2011, European journal of cancer.

[16]  Zoe Wainer,et al.  Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  T. Walles,et al.  Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon , 2011, European Respiratory Journal.

[18]  A. Nicholson,et al.  Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification , 2011, European Respiratory Journal.

[19]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[20]  M. Tsao,et al.  A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Y. Ung,et al.  Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Masahiro Fukuoka,et al.  Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  William Pao,et al.  Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma , 2011, European Respiratory Journal.

[24]  J. Lafitte,et al.  Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations , 2011, European Respiratory Journal.

[25]  P. Prorok,et al.  Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. , 2011, Journal of the National Cancer Institute.

[26]  J. Temel,et al.  Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2011. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  A. Dirksen,et al.  Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial , 2010, Thorax.

[30]  A. Nicholson,et al.  Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. , 2012, European journal of cancer.

[31]  S. Salah,et al.  Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: systematic review and analysis of reported cases. , 2012, Lung cancer.

[32]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[33]  A. Tsao.  Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care , 2012 .

[34]  N. M. González Senac.  [Suicide and cardiovascular death after a cancer diagnosis]. , 2012, Revista clinica espanola.

[35]  Liu Yan-hui,et al.  Interpretation of Pathological Perspective——International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011 .

[36]  C. Jansen,et al.  Severity: A meta-analysis , 2006 .

[37]  Bernard Maitre,et al.  Screening by Chest Radiograph and Lung Cancer Mortality : The Prostate , Lung , Colorectal , and Ovarian ( PLCO ) Randomized Trial , 2022 .